Type 2 diabetes (T2D) is a risk factor for cataract development. With T2D prevalence increasing, the burden of cataract-associated vision loss will also increase. We aimed to characterise cataract diabetes-specific risk factors to assist prevention and management strategies. As part of a systematic review, two investigators independently searched online electronic databases according to a predetermined protocol for relevant published data to end-March 2018. Studies were included if they were longitudinal with ≥100 participants, diabetes was defined, a description of cataract assessment was provided, data were from humans, and the reports were in English.
| INTRODUCTION
Cataracts are a clouding of the lens of the eye that impair vision. They are the leading cause of blindness globally and the second highest cause of visual impairment after refractive error. 1 The only effective, approved treatment is an intraocular lens (IOL) implant which is now generally performed as a day-case procedure. In most high-income countries, 5% of the prevalent cases of blindness are attributable to cataract, reflecting relatively prompt access to cataract surgery (CS). 2 By contrast, the prevalence of blindness from cataracts often exceeds 50% in developing countries with limited health infrastructure. 2 Cataracts are associated with significant direct and indirect costs. 3 For example, it has been estimated that CS cost AU$326.6 million in Australia in 2004. 4 Although IOL surgery is a cost-effective solution to cataract-associated vision loss, cost utility values remain substantial, ranging from US$9 to $1600/quality adjusted life year in developing countries to US$245 to $22 000/quality adjusted life year in developed countries. 5 There is, therefore, a strong health economic argument for improved cataract prevention through better risk factor management.
Diabetes is a recognised risk factor for cataract development that is increasing in prevalence worldwide. 6 The International Diabetes
Federation estimated there were 382 million people aged between 20 and 79 years with diabetes in 2013 and expect this to increase to 592 million by 2035. 7 Type 2 diabetes (T2D), which comprises approaching 90% of all cases of diabetes, 8 is associated with approximately double the risk of cataract compared with the general population, 6 with significant increases in both cortical cataracts (CC) and posterior subcapsular cataracts (PSC). 6 There are many plausible pathophysiological mechanisms that could underlie the increased risk of cataracts in diabetes including perturbations in the polyol and oxidative stress pathways and in the unfolded protein response. [9] [10] [11] It is likely these mechanisms are reflected in risk factor profiles for cataracts and associated blindness that are specific to T2D, including those that could be targeted as part of cataract prevention. The aim of the present systematic review was, therefore, to characterise the risk factors for cataract complicating T2D.
| MATERIALS AND METHODS

| Search strategy and selection criteria
The Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols 2015 protocol guidelines were followed in protocol development. 12 Electronic searches of Embase, PubMed, and MEDLINE databases were conducted. The Boolean search term used was "diabetes
AND (cataract OR lens opacity OR IOL OR clouding of lens) AND (risk OR predictors OR determinants OR incidence)." Longitudinal studies
were eligible for inclusion if written in English, participants were humans, diabetes was defined, the criteria for determining cataract status were described, and people with T2D who developed a cataract were compared with people with T2D who did not. A minimum sample size of 100 participants was applied to minimise publication bias. To ensure reasonable quality, the statistical analyses used in observational studies were required to include, as a minimum, a model adjusted for age and sex. For multiple reports from the same population, the most recent paper was included unless there were separate publications focussing on different risk factors or cataract outcomes. The search included articles published at end-March 2018. The summary measures used were those reported in individual studies. These included relative risk, odds ratios, and hazard ratios. Mostly, the randomised control trials (RCTs) utilised relative risk and the observational studies used odds ratios.
Two reviewers (J.D. and W.D.) independently conducted the literature search and reviewed all the articles, assessing eligibility and extracting the required information. Data from the eligible studies were entered into pre-defined fields including the country where the research was performed, aims, methods, results, definitions, sample size, covariates included in analysis, and limitations. The references cited in all the eligible published studies were reviewed to identify articles that had been missed in the initial search but which met the inclusion criteria. The results of the search performed by each reviewer were compared for consistency and completeness. The risk of bias was assessed using the Cochrane handbook guidelines. 13 The quality of observational studies was assessed using the Newcastle Ottawa Quality Assessment Form for Cohort Studies, 14 with a median follow-up time of 2 years required for Outcome question 2, as change over this time frame was significant in other similar studies. 15 The level of evidence from RCTs was assessed using GRADE. 16 Although a meta-analysis was planned, this was not appropriate.
| RESULTS
The electronic database search identified 5255 publications. After exclusions, 18 journal articles were eligible, and one additional paper was identified from cited references giving a total of 19 relevant articles of which four were RCTs (see Figure 1 ). ClinicalTrials.gov number NCT00000151) included people with diabetes, but not specifically T2D. 17, 28 However, both the BDES and ETDRS were included in the review as they were considered FIGURE 1 Consort diagram important landmark studies. In the ETDRS, approximately 30% of participants had T2D, and the BDES investigators assumed that 90% of their study population would have had T2D. The Wisconsin Epidemiology Study of Diabetic Retinopathy incorporated older and younger diabetes onset groups. 29 The older group was considered to have T2D for the purposes of the present review.
The characteristics of the included studies are shown in Table 1 .
Five were conducted in the US, three in the UK, and one each in Taiwan, Sweden, Iran, and India, and one multi-centre study was conducted over two countries (the US and Canada). Sample sizes ranged from 172 to 27 232 participants. Follow-up times varied.
One study used a pre-established database with up to 26 years of follow-up, but there was at least a mean or median follow-up of 2 years in the other studies. The Veterans Affairs Diabetes Trial (ClinicalTrials.gov number NCT00032487) had mostly (93.1%) male participants, but there were between 30.7% and 65.3% females in the other studies.
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The methods and limitations of each included study are shown in Table 2 . Convenience sampling from existing clinical practices with an attendant risk of selection bias and use of registry data which raises reliability and validity concerns were common limitations. A limitation in some RCTs was the risk of blinding bias as investigators knew which participants were randomised to intensive glycaemic or blood pressure control versus usual care. Although conflicts of interest were unlikely in these studies, all the RCTs, apart from the ETDRS, declared receipt of funding from pharmaceutical companies.
The definitions and outcomes are summarised in Table 3 . The definitions for T2D varied, with three using the updated 1997 American Diabetes Association (ADA) or 1999 World Health Organisation criteria, two using older criteria, and others using medical record coding, physician diagnosis, or self-report. There were five main cataractrelated outcomes; any cataract (AC), CS, nuclear cataract (NC), PSC, and CC. In addition, the Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetic Study II (SN-DREAMS II) identified nuclear opalescence and nuclear colour, 31 and the ETDRS study identified a visually significant lens opacity. 17 Five of the studies determined risk factors for cataract subtypes and six determined risk factors for CS. The worst eye was generally used in analyses. One study did not compare those with cataracts to those with no cataracts, instead comparing those with versus without one sub-type. 31 The findings were collated according to the different cataract outcomes as shown in Table 4 . Apart from age and glycaemic control, there was limited consistency across the risk factors. There were 12 risk factors identified by only one of the included studies, which complicated its interpretation. The risks of bias are shown in Table 5 .
Only the Kinmen study had a high risk of bias in more than one category. [25] [26] [27] The observational studies were of good quality based on the Newcastle-Ottawa Scale for cohort studies with the number of stars in the included studies ranging from 6 to 8 out of 9.
The RCTs focused on the effects of glycaemic control, hypertension, and/or aspirin use on CS. No significant association (odds ratio
[OR] and 95% confidence intervals [CI] 0.88 (0.76-1.03) was found in a prior meta-analysis of the effect of intensive glycaemic control on CS. 39 As there were not sufficient other RCTs with the same risk factors (two on hypertension, one on dyslipidaemia, and one on aspirin), no updated meta-analysis was conducted. The GRADE quality of the studies included in the intensive glycaemic control meta-analysis was low, due to blinding bias and variability across studies. Six observational studies did not include diabetes treatment as a variable in the modelling. [25] [26] [27] [28] 31, 35 Two other studies identified diabetes treatment as a covariate. One of these split the results by insulin treatment, and the other was a retrospective study without diabetes treatment available at earlier time points. 33, 36 Taken together, these studies suggest that intensive diabetes treatment is not associated with cataract development despite observational studies showing increased odds of cataract with treatment when compared with diet-based management. However, the available evidence is of low quality, inconsistent, and may have come from studies with a duration of follow-up which is insufficient for cataracts to become clinically evident. Given that diabetes treatment may be a surrogate marker of prior poor glycaemic control and that progression to insulin therapy may reflect duration of diabetes, the relationship between cataract and diabetes treatment appears complex.
| DISCUSSION
Three observational studies found diabetes duration was associated with cataract. An increased odds (OR 1.1 [95%CI:
year, P = 0.01) of PSC cataract was found with increasing diabetes duration in the SN-DREAMS II study. 31 However, this study did not have a baseline ophthalmic assessment so differentiation between prevalent and incident cataract was not possible, and there were limited variables included in the regression analysis. Becker et al also found the odds of cataract to be increased if diabetes duration was ≥2 years in one of two models that focussed on the effect of medications, but their model did not adjust for glycaemic control or diabetes treatment. 32 [25] [26] [27] 29, 33 As only three studies reported a significant relationship between diabetes duration and cataract development, with differing directions of association and methodological concerns, while others reported no statistically significant association, it is unlikely that diabetes duration per se significantly contributes to cataract development.
The effects of lipids on cataract development in T2D are inconsistent in available studies. The lipid-lowering arm of the ACCORD Eye study (ClinicalTrials.gov number NCT00542178) showed no significant association with CS. 21 Most of the observational studies included total serum cholesterol as a candidate predictor and found no association. 19, 28, 31, 33, 34 By contrast, dyslipidaemia was a risk factor for cataract in the study by Becker et al. 32 Serum triglycerides also significantly increased the odds of cataract in the Kinmen studies with a serum triglyceride ≥2 mmol/L at baseline associated with increased Mostly a consistent increased risk of cataract was found with increasing HbA 1c , apart from one, possibly spurious finding, which showed it was protective, for PSC subtype 31 Fasting blood glucose Two studies showed increased odds of cataract surgery with insulin use, 29, 32 one study showed an oral agent was protective of any cataract when compared with diet One RCT showed intensive diabetes treatment was significantly protective while three other RCTs showed no association. [20] [21] [22] [23] Cataract was not the primary outcome of the RCTs so there would be less power in these subgroup analyses.
Blood pressure The Kinmen study found triglycerides were positively associated with any cataract and NC cataract 25, 27 and Becker found dyslipidaemia was associated with any cataract. 32 The ACCORD eye RCT found no significant association in their lipid trial for intensive versus standard treatment 21 Diabetes duration In contrast, Janghorbani et al showed a negative association but included age, diabetes duration and age at diagnosis in their model. 34 Any retinopathy The lens membrane contains high concentrations of cholesterol and cholesterol oxidation is a plausible mechanism of action through which dyslipidemia may contribute to cataract development. 43 Serum lipids have been associated with cataract development, although not consistently, in the general population. High density lipoprotein cholesterol was shown to be protective against CC in females in the BDES, 44 and hypercholesterolaemia was a risk factor for development of any type of cataract in the Korean National Health And Nutrition Examination Survey. 45 A meta-analysis using a combination of randomised and observational studies concluded that statin therapy was protective against AC and CS in the general population. 46 Although clinically plausible, a similar effect of lipids on the development of cataract in people with T2D cannot be established given the insufficient published evidence.
Blood pressure and smoking do not appear to contribute to cataracts in people with T2D. Two RCTs, the UKPDS and the ACCORD Eye Study, found no significant association with intensive blood pressure control and CS compared with standard treatment. 19, 21, 24 By contrast, blood pressure was inconsistently associated with cataract in two observational studies. Becker et al found hypertension increased, while Tung et al found diastolic blood pressure ≥ 90 mmHg (after adjusting for blood pressure lowering medication) decreased, the odds of cataract. 25, 32 There was no association in the other observational studies. Hypertension has been shown to contribute to AC and PSC in the general population in a meta-analysis. 47 However, there is no consistent evidence that hypertension is a risk factor for cataract in T2D. Hypertension is associated with the risk of development of diabetes which could mask an association. 48 Smoking has been associated with increased odds of age-related cataract, NC and PSC in the general population, a finding which was replicated in two studies in the present review. 32, 34, 49 By contrast, five other studies reported no significant association in T2D. 28, 29, 33, 35, 36 As with hypertension, smoking is an independent risk factor for the development of diabetes which may confound the association with cataract. 50 Diabetic retinopathy was significantly associated with an increased risk of AC in the non-insulin treated group of the Nottingham study and with an increased odds of CS in the Kinmen study. 26, 36 These were the only studies in our review that assessed diabetic retinopathy as a risk factor. Since there is no established mechanism through which diabetic retinopathy contributes to cataract development, it is possible that an association is due to the "common soil"
hypothesis in which risk factors for cataract and diabetic retinopathy, including oxidative stress and hyperglycaemia, are shared. 51 Retinopathy is thought to worsen after CS in people with diabetes, but advances in surgical techniques are likely to have substantially attenuated this risk. 52, 53 In addition, low grade retinopathy may be masked by lens opacities and only detected at the time of CS. 54 In the Kinmen study, diabetic retinopathy and CS were assessed at the same time, 6
to 8 years after baseline. 26 As the Kinmen Study ocular assessment was conducted in 1999 in a rural area in a developing country, it is possible that the basic cataract surgical techniques available at the time contributed to retinopathy progression. However, the overall evidence suggests that that diabetic retinopathy is not a risk factor for cataract development.
Age at diabetes diagnosis, sex, heart rate, body mass index, hyperopia, dietary supplements, asthma, ischaemic heart disease, congestive heart failure, myocardial infarction, corticosteroid use, and chronic obstructive pulmonary disease were identified as risk factors by only single studies in the present review, as shown in Table 4 . It is unlikely that sex is a risk factor for cataract in people with T2D as this was adjusted for in all the studies. Aspirin was not associated with cataract in the ETDRS 17 but was not assessed in the other included studies.
Overall, these other variables have not consistently shown a significant association with cataract in a population with T2D, although some have been found to contribute to cataracts in the general population. 40 The strengths of the present review include the extensive literature search by two reviewers who followed a predetermined protocol. The studies included were analysed for level of bias and quality using recognised grading systems and most were of high quality. However, only studies that were available in English were included. Secondly, the present review included studies performed before and after the ADA and World Health Organisation reduced the glycaemic threshold for diabetes diagnosis. Due to the small numbers of recent studies, it was thought appropriate to include all relevant studies. Thirdly, the criteria and definitions of cataract varied. While most studies used a standardised method of assessing cataracts, there were many different cataract outcomes. These provided limited information when examined separately as so the data were pooled. As a result, caution should be exercised when interpreting these findings, especially if extrapolating the results to specific cataract sub-types.
There is convincing evidence that age and glycaemic control increase the risk of cataract in T2D. Although glycaemia is potentially modifiable, studies of the relationship between intensified blood glucose-lowering treatment and the development of cataracts in T2D
do not show a consistent effect, perhaps because of the likely long time course of cataract development compared with the duration of follow-up in observational studies and RCTs. Apart from these two strong risk factors, the role of other potentially contributing variables such as dyslipidaemia and smoking is not well established. There are too few studies to assess whether chronic obstructive pulmonary disease, ischaemic heart disease, congestive heart failure, myocardial infarction, corticosteroid use, asthma, dietary supplements, BMI, and hyperopia are associated with cataract in T2D, but sex, aspirin use, blood pressure, and diabetes duration do not appear to be important determinants of cataract development based on the results of the present systematic review.
Additional well-conducted, long-term studies in T2D are needed, in which cataract-related outcomes and candidate risk factors are rigorously defined. Such studies have added importance as there is evidence that T2D-associated mortality is declining due to improved cardiovascular risk factor management, 55, 56 with the result that more years spent living with diabetes will increase the likelihood of nonlife-threatening complications such as cataract. 57 Since impaired vision has a substantial impact on quality of life, the risk of falls, and death in the elderly, 58, 59 an improved understanding of the determinants of cataract complicating T2D should lead to improved identification and multifactorial management of those at risk.
